# Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

> **NCT03095248** · PHASE2 · TERMINATED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 10 (actual)

## Conditions studied

- Neurofibromatosis 2
- Vestibular Schwannoma
- Meningioma
- Ependymoma
- Glioma

## Interventions

- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT03095248
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-08
- **Primary completion:** 2024-05-21
- **Final completion:** 2024-05-21
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Results review of patient data
- **Last updated:** 2025-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03095248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03095248, "Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03095248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*